• FirefoxInstall the new Firefox »
  •  Dow Down0.45% Nasdaq Down0.49%

    Acura Pharmaceuticals, Inc. (ACUR)

    -NasdaqCM
    0.85 Up 0.09(11.84%) Feb 27, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Acura Pharmaceuticals, Inc.
    616 N. North Court
    Suite 120
    Palatine, IL 60067
    United States - Map
    Phone: 847-705-7709
    Fax: 847-705-5399
    Website: http://www.acurapharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Delivery
    Full Time Employees:15

    Business Summary 

    Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company’s products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Acura Pharmaceuticals, Inc.

    Corporate Governance 
    Acura Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Robert B. Jones , 56
    Chief Exec. Officer, Pres and Director
    509.00K0.00
    Mr. Peter A. Clemens , 62
    Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
    291.00K2.00K
    Dr. Albert W. Brzeczko Ph.D., 58
    VP of Technical Affairs
    332.00K0.00
    Mr. J. Bradley Rivet , 61
    VP of Marketing
    171.00K0.00
    Mr. Robert A. Seiser , 51
    VP, Treasurer and Corp. Controller
    200.00K10.00K
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders